Literature DB >> 17539996

In vivo transfection of C/EBP-alpha gene could ameliorate CCL(4)-induced hepatic fibrosis in mice.

Shuang Mei1, Xueqing Wang, Jinsheng Zhang, Jin Qian, Juling Ji.   

Abstract

AIM: Hepatic stellate cells (HSCs) play a key role in liver fibrosis. CCAAT/enhancer-binding proteins-alpha (C/EBP-alpha) can inhibit HSCs activation in vitro, as described in our previous study. However, little is known about the in vivo effect of C/EBP-alpha gene in hepatic fibrosis.
METHODS: Male BALB/c mice were injected by hydrodynamic protocol with pIRES2-EGFP-C/EBPalpha expression vector from the first to the fourth week (early intervention) or from the ninth to the 12th week (late intervention) after CCl(4) injection, respectively. Successful transfection of vector and the expression of C/EBP-alpha were confirmed with the appearance of green fluorescence in liver cells, immunohistochemical staining and the western blot.
RESULTS: High expression of C/EBP-alpha gene in liver cells, especially in non-parenchymal cells, could reduce the content of collagens by 82.5% and 72.3% (Sirius red staining + image analysis) and the content of hydroxyproline by 56.3% and 51.6%, respectively, in the early and late intervention experiments.
CONCLUSION: It is evident that exogenous C/EBP-alpha gene has an early and late intervention role in mice liver fibrosis.

Entities:  

Year:  2007        PMID: 17539996     DOI: 10.1111/j.1872-034X.2007.00074.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  5 in total

1.  GROWTH AND DEVELOPMENT SYMPOSIUM: STEM AND PROGENITOR CELLS IN ANIMAL GROWTH: The regulation of beef quality by resident progenitor cells1.

Authors:  Xing Fu; Chaoyang Li; Qianglin Liu; Kenneth W McMillin
Journal:  J Anim Sci       Date:  2019-05-30       Impact factor: 3.159

2.  Trichostatin A inhibits the activation of Hepatic stellate cells by Increasing C/EBP-α Acetylation in vivo and in vitro.

Authors:  Di Ding; Lin-Lin Chen; Ying-Zhen Zhai; Chen-Jian Hou; Li-Li Tao; Shu-Han Lu; Jian Wu; Xiu-Ping Liu
Journal:  Sci Rep       Date:  2018-03-13       Impact factor: 4.379

3.  Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.

Authors:  Vikash Reebye; Kai-Wen Huang; Vivian Lin; Sheba Jarvis; Pedro Cutilas; Stephanie Dorman; Simona Ciriello; Pinelopi Andrikakou; Jon Voutila; Pal Saetrom; Paul J Mintz; Isabella Reccia; John J Rossi; Hans Huber; Robert Habib; Nikos Kostomitsopoulos; David C Blakey; Nagy A Habib
Journal:  Oncogene       Date:  2018-03-07       Impact factor: 9.867

4.  Liraglutide Exerts Protective Effects by Downregulation of PPARγ, ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis and Drug-Induced Steatosis.

Authors:  Tea Omanovic Kolaric; Tomislav Kizivat; Vjera Mihaljevic; Milorad Zjalic; Ines Bilic-Curcic; Lucija Kuna; Robert Smolic; Aleksandar Vcev; George Y Wu; Martina Smolic
Journal:  Curr Issues Mol Biol       Date:  2022-08-02       Impact factor: 2.976

5.  Lipopolysaccharide Reverses Hepatic Stellate Cell Activation Through Modulation of cMyb, Small Mothers Against Decapentaplegic, and CCAAT/Enhancer-Binding Protein C/EBP Transcription Factors.

Authors:  Akanksha Sharma; Alok K Verma; Matthew Kofron; Ramesh Kudira; Alexander Miethke; Tong Wu; Jiang Wang; Chandrashekhar R Gandhi
Journal:  Hepatology       Date:  2020-10-22       Impact factor: 17.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.